Keros Therapeutics, Inc.

NasdaqGM KROS

Keros Therapeutics, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2024

Keros Therapeutics, Inc. Return on Equity (ROE) is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

Keros Therapeutics, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2023 was -44.45%, a -38.04% change year over year.
Keros Therapeutics, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2022 was -32.20%, a -24.23% change year over year.
Keros Therapeutics, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2021 was -25.92%, a 43.15% change year over year.
Keros Therapeutics, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2020 was -45.59%.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

NasdaqGM: KROS

Keros Therapeutics, Inc.

CEO	Dr. Jasbir S. Seehra Ph.D.
IPO Date	April 8, 2020
Location	United States
Headquarters	99 Hayden Avenue
Employees	160
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Key trends

Past 5 years